OncoMatch/Clinical Trials/NCT07061951
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Is NCT07061951 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Mirdametinib for recurrent chronic lymphocytic leukemia.
Treatment: Mirdametinib — This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mirdametinib, a methyl ethyl ketone (MEK) inhibitor, works by blocking the action of an abnormal protein that signals cancer cells to multiply. This may help slow or stop the spread of cancer cells. Giving mirdametinib may be effective in treating patients with relapsed or refractory CLL or SLL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: Bruton's tyrosine kinase inhibitor
Patients must have received at least two prior therapies for CLL including systemic therapy containing a Bruton's tyrosine kinase (BTK) inhibitor
Must have received: BCL2 inhibitor
Patients must have received at least two prior therapies for CLL including systemic therapy containing...a BCL2 inhibitor
Lab requirements
Blood counts
Absolute neutrophil count ≥ 500/mcL (growth factor allowed; 250 permitted for patients with bone marrow involvement); Platelets ≥ 20,000/mcL independent of transfusion within 7 days of screening (transfusion permitted for bone marrow involvement)
Kidney function
Glomerular filtration rate (GFR) 50 ml/min estimated using CKD-EPI
Liver function
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome, autoimmune hemolytic anemia (AIHA), or of non-hepatic origin; AST/ALT ≤ 3 x institutional ULN
Cardiac function
New York Heart Association Functional Classification class II or better; QTc ≤ 470 ms
Absolute neutrophil count ≥ 500/mcL...Platelets ≥ 20,000/mcL...Total bilirubin ≤ 1.5 x institutional ULN...AST/ALT ≤ 3 x institutional ULN...GFR 50 ml/min...NYHA class II or better...QTc ≤ 470 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify